Microbiology, Caspofungin, Candida albicans, Echinocandin and Corpus albicans are his primary areas of study. His Microbiology study incorporates themes from Anidulafungin and Mutant. His Anidulafungin research is multidisciplinary, incorporating perspectives in Multilocus sequence typing, Fungal protein and Caspofungin Acetate.
The Mutant study combines topics in areas such as Candida glabrata, Echinocandins and Candida krusei. His study in Candida albicans focuses on Antifungal drug in particular. His research in Aspergillus fumigatus intersects with topics in Aspergillosis and Aspergillus.
Steven Park mostly deals with Microbiology, Aspergillus fumigatus, Candida albicans, Echinocandin and Caspofungin. Steven Park has included themes like Mutant, Fungal protein and Micafungin in his Microbiology study. His study on Aspergillus fumigatus also encompasses disciplines like
His biological study spans a wide range of topics, including Fungi imperfecti and Ergosterol. His Echinocandin research integrates issues from Anidulafungin and Biochemistry. Steven Park interconnects Antifungal drug and Staphylococcus aureus in the investigation of issues within Drug resistance.
Steven Park focuses on Microbiology, Antibiotics, Tuberculosis, Pharmacokinetics and Pathology. Steven Park specializes in Microbiology, namely Drug resistance. His work on Multiple drug resistance as part of general Drug resistance study is frequently linked to Bacterial genetics, bridging the gap between disciplines.
His Antibiotics research is multidisciplinary, incorporating elements of Natural product and Bacteria. His research on Tuberculosis also deals with topics like
His scientific interests lie mostly in Bacteria, Microbiology, Antibiotics, Microbiome and Tuberculosis. His studies in Bacteria integrate themes in fields like Gene expression, Gene, Lipid II, Human microbiome and Natural product. His study brings together the fields of Nonribosomal peptide and Microbiology.
His study in Microbiome is interdisciplinary in nature, drawing from both Medical microbiology, Multiple drug resistance, Drug resistance and Staphylococcus aureus. His Tuberculosis research includes themes of Pharmacokinetics and Potency. Steven Park has researched Pathology in several fields, including In vivo and Drug.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates
S. Park;R. Kelly;J. Nielsen Kahn;J. Robles.
Antimicrobial Agents and Chemotherapy (2005)
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
Guillermo Garcia-Effron;Santosh K. Katiyar;Steven Park;Thomas D. Edlind.
Antimicrobial Agents and Chemotherapy (2008)
High-frequency Triazole Resistance Found In Nonculturable Aspergillus fumigatus from Lungs of Patients with Chronic Fungal Disease
David W. Denning;Steven Park;Cornelia Lass-Florl;Marcin G. Fraczek;Marcin G. Fraczek.
Clinical Infectious Diseases (2011)
Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Guillermo Garcia-Effron;Samuel Lee;Steven Park;John D. Cleary.
Antimicrobial Agents and Chemotherapy (2009)
Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole
Adriana M. Nascimento;Gustavo H. Goldman;Steven Park;Salvatore A. E. Marras.
Antimicrobial Agents and Chemotherapy (2003)
Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens.
Bradley M. Hover;Seong Hwan Kim;Micah Katz;Zachary Charlop-Powers.
Nature microbiology (2018)
Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.
Guillermo Garcia-Effron;Steven Park;David S. Perlin.
Antimicrobial Agents and Chemotherapy (2009)
Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1
Sergey V. Balashov;Steven Park;David S. Perlin;David S. Perlin.
Antimicrobial Agents and Chemotherapy (2006)
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis
Michel Laverdière;Richard G. Lalonde;Jean Guy Baril;Donald C. Sheppard.
Journal of Antimicrobial Chemotherapy (2006)
Multi-azole resistance in Aspergillus fumigatus
Susan J. Howard;Ian Webster;Caroline B. Moore;Rebecca E. Gardiner.
International Journal of Antimicrobial Agents (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: